These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 6752720)
1. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. Greene MH; Boice JD; Greer BE; Blessing JA; Dembo AJ N Engl J Med; 1982 Dec; 307(23):1416-21. PubMed ID: 6752720 [TBL] [Abstract][Full Text] [Related]
2. Acute leukemia after alkylating-agent therapy of ovarian cancer. Reimer RR; Hoover R; Fraumeni JF; Young RC N Engl J Med; 1977 Jul; 297(4):177-81. PubMed ID: 406560 [TBL] [Abstract][Full Text] [Related]
3. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Greene MH; Young RC; Merrill JM; DeVita VT Cancer Res; 1983 Apr; 43(4):1891-8. PubMed ID: 6572558 [TBL] [Abstract][Full Text] [Related]
5. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. Curtis RE; Boice JD; Stovall M; Bernstein L; Greenberg RS; Flannery JT; Schwartz AG; Weyer P; Moloney WC; Hoover RN N Engl J Med; 1992 Jun; 326(26):1745-51. PubMed ID: 1594016 [TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia and other myelopathic disorders following treatment with alkylating agents. Bennett JM; Moloney WC; Greene MH; Boice JD Hematol Pathol; 1987; 1(2):99-104. PubMed ID: 3504435 [TBL] [Abstract][Full Text] [Related]
7. Acute leukaemia after alkylating-agent therapy of ovarian cancer. Bell DR; Woods RL; Levi JA Med J Aust; 1982 Sep; 2(5):243-4. PubMed ID: 7132879 [No Abstract] [Full Text] [Related]
8. Leukemia following chemotherapy for breast cancer. Curtis RE; Boice JD; Moloney WC; Ries LG; Flannery JT Cancer Res; 1990 May; 50(9):2741-6. PubMed ID: 2328500 [TBL] [Abstract][Full Text] [Related]
9. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. Travis LB; Holowaty EJ; Bergfeldt K; Lynch CF; Kohler BA; Wiklund T; Curtis RE; Hall P; Andersson M; Pukkala E; Sturgeon J; Stovall M N Engl J Med; 1999 Feb; 340(5):351-7. PubMed ID: 9929525 [TBL] [Abstract][Full Text] [Related]
10. Leukemia after treatment of ovarian cancer with alkylating agents. Parker LM N Engl J Med; 1983 Jun; 308(23):1422. PubMed ID: 6843637 [No Abstract] [Full Text] [Related]
11. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). Boice JD; Greene MH; Killen JY; Ellenberg SS; Keehn RJ; McFadden E; Chen TT; Fraumeni JF N Engl J Med; 1983 Nov; 309(18):1079-84. PubMed ID: 6353233 [TBL] [Abstract][Full Text] [Related]
12. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. Wadler S; Yeap B; Vogl S; Carbone P Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766 [TBL] [Abstract][Full Text] [Related]
13. Leukemia following chemotherapy for ovarian cancer. Kaldor JM; Day NE; Pettersson F; Clarke EA; Pedersen D; Mehnert W; Bell J; Høst H; Prior P; Karjalainen S N Engl J Med; 1990 Jan; 322(1):1-6. PubMed ID: 2104664 [TBL] [Abstract][Full Text] [Related]
14. Characteristics of secondary acute nonlymphocytic leukemias. Cytological aspects (a review). Raposa T; Várkonyi J; Gráf F Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(2):180-5. PubMed ID: 6208100 [TBL] [Abstract][Full Text] [Related]
15. Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary. Dusenbery KE; Bellairs EE; Potish RA; Twiggs LB; Boente MP Gynecol Oncol; 2005 Feb; 96(2):307-13. PubMed ID: 15661213 [TBL] [Abstract][Full Text] [Related]
16. Leukemia after therapy with alkylating agents for childhood cancer. Tucker MA; Meadows AT; Boice JD; Stovall M; Oberlin O; Stone BJ; Birch J; Voûte PA; Hoover RN; Fraumeni JF J Natl Cancer Inst; 1987 Mar; 78(3):459-64. PubMed ID: 3469460 [TBL] [Abstract][Full Text] [Related]
17. [Plasmocytoma, alkylating agents, and acute myeloid leukemia (author's transl)]. Schmalzl F; Keiser G; Kresbach E; Fritz H; Asamer H; Braunsteiner H Dtsch Med Wochenschr; 1975 Sep; 100(39):1961-7. PubMed ID: 1057506 [TBL] [Abstract][Full Text] [Related]
18. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578 [TBL] [Abstract][Full Text] [Related]
19. Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer. Lerner HJ Cancer Treat Rep; 1978 Aug; 62(8):1135-8. PubMed ID: 278642 [TBL] [Abstract][Full Text] [Related]
20. Melphalan may be a more potent leukemogen than cyclophosphamide. Greene MH; Harris EL; Gershenson DM; Malkasian GD; Melton LJ; Dembo AJ; Bennett JM; Moloney WC; Boice JD Ann Intern Med; 1986 Sep; 105(3):360-7. PubMed ID: 3740675 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]